<DOC>
	<DOCNO>NCT00002564</DOCNO>
	<brief_summary>RATIONALE : Dietary fat may involve growth cancer cell . Restricting dietary fat may help fight cancer . PURPOSE : Randomized clinical trial study effectiveness low fat diet treat postmenopausal woman stage I , stage II , stage IIIA breast cancer completely remove surgery .</brief_summary>
	<brief_title>Nutrition Intervention Treating Women With Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Determine whether dietary fat reduction effectively prolong disease-free overall survival woman surgically treat early stage breast cancer receive adjuvant therapy without either tamoxifen , cyclophosphamide , methotrexate , fluorouracil ( CMF ) , doxorubicin , cyclophosphamide ( AC ) , fluorouracil , doxorubicin , cyclophosphamide ( FAC , CAF ) , AC follow paclitaxel . II . Evaluate whether difference lipid profile associate dietary group assignment dietary fat . OUTLINE : This randomize , multicenter study . Patients stratify center , nodal status , ER status , type adjuvant chemotherapy . The first group receive intensive dietary intervention reduction total fat intake 15 % calorie , repeat individual group counsel session . The second group receive USDA/DHHS dietary guideline minimal intervention . All patient estrogen receptor positive receive concurrent therapy tamoxifen ; cyclophosphamide , methotrexate , fluorouracil ( CMF ) follow tamoxifen ; doxorubicin , cyclophosphamide ( AC ) follow tamoxifen ; fluorouracil , doxorubicin , cyclophosphamide ( FAC , CAF ) follow tamoxifen ; AC , paclitaxel follow tamoxifen . Patients follow annually throughout study . PROJECTED ACCRUAL : Approximately 2,500 woman accrue study .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven , invasive , localized carcinoma breast Stage I/II/IIIA disease , i.e . : Tumor confine breast clinical examination Overlying skin movable respect tumor Tumor movable relation underlie muscle chest wall Bone scan and/or xray require rule bone metastases case skeletal pain Tumor size requirement : No great 5 cm lymph node positive Greater 1 cm lymph node negative Tumor definitively treat one follow procedure : Total mastectomy axillary node dissection Segmental mastectomy without axillary node dissection and/or sentinel node biopsy follow breast irradiation , provide : Surgical margin histologically free invasive noninvasive tumor One additional resection allow obtain clear margin Total mastectomy require clear margin obtain second resection The following condition exclude : Bilateral malignancy mass contralateral breast unless proven nonmalignant biopsy Palpable lymph node contralateral axilla probable supraclavicular infraclavicular nodal involvement unless proven nonmalignant biopsy 10 positive lymph node Inflammatory breast cancer Ulceration erythema Infiltration skin peau d'orange Tethering dimple skin nipple inversion consider skin infiltration Satellite breast nodule Parasternal nodule Edema arm Hormone receptor status : Any estrogen receptor ( ER ) progesterone receptor ( PR ) status allow ER assessment require PR assessment recommend Less 365 day definitive surgery randomization PATIENT CHARACTERISTICS : Age : 48 78 Sex : Female Menopausal status : Postmenopausal Performance status : Not specify Life expectancy : At least 10 year ( exclude breast cancer ) Hematopoietic : WBC least 3,000/mm3 Platelet count least 100,000/mm3 Hepatic : Bilirubin great 1.5 mg/dL AST great 60 IU/mL ( within 2 time normal ) Renal : Creatinine great 1.5 mg/dL Cardiovascular : No active cardiac disease would preclude doxorubicin patient assign adjuvant chemotherapy doxorubicin Other : Baseline caloric intake least 20 % fat Accessible followup telephone Sufficient memory require provide food recall data Must speak read English Medically nutritionally eligible either dietary intervention arm No prior concomitant malignancy except curatively treat nonmelanoma skin cancer carcinoma situ cervix PRIOR CONCURRENT THERAPY : No concurrent participation another adjuvant breast cancer trial diseasefree overall survival study endpoint ( e.g. , major cooperative group trial ) Biologic therapy : Not specify Chemotherapy : Concurrent adjuvant cyclophosphamide , methotrexate , fluorouracil ( CMF ) , doxorubicin , cyclophosphamide ( AC ) , AC follow paclitaxel , fluorouracil/doxorubicin/cyclophosphamide ( FAC , CAF ) allow If ER negative , approve chemotherapy regimen and/or tamoxifen require No 120 day definitive surgery initiation adjuvant systemic chemotherapy Endocrine therapy : Concurrent adjuvant tamoxifen require ER positive ( ER negative , tamoxifen and/or approve chemotherapy regimen require ) No 180 day definitive surgery initiation tamoxifen ( receive tamoxifen alone ) If receive adjuvant CMF , AC , FAC , CAF , AC , paclitaxel , tamoxifen begin completion adjuvant therapy Radiotherapy : Radiotherapy require within 56 day follow segmental mastectomy Surgery : Definitive surgery require Prior oophorectomy reason malignancy allow</criteria>
	<gender>Female</gender>
	<minimum_age>48 Years</minimum_age>
	<maximum_age>78 Years</maximum_age>
	<verification_date>February 2010</verification_date>
	<keyword>recurrent breast cancer</keyword>
</DOC>